MetLife, Inc. (MET) Down 4.7% — Is It Time to Part Ways?
MetLife, Inc. (MET) retreated sharply on the session, dropping 4.72% from the prior close of $79.10 to finish at $75.36. That move erased $3.74 in a single day, leaving the stock squarely under pressure after surrendering recently reclaimed ground. The decline also pulled MET further from its earlier peak, reinforcing the choppy tone that has kept shares facing headwinds in the near term.
Trading activity was lighter than usual. Volume came in at roughly 1.15 million shares — well below the 90-day average of approximately 3.58 million — suggesting the selloff unfolded without the broad participation that typically signals strong conviction. Even so, the price action was decisive. The latest slide widened the gap to MET's 52-week high of $87.39, set on 03/03/2025. At $75.36, MET sits about $12.03 below that mark — roughly 13.8% off the high — underscoring how far the shares have retreated from their best levels of the past year.
Within the insurance industry, MET's one-day decline stood out for its severity; the stock lost considerably more ground than investors would typically expect from large, well-established peers like Ping An (PNGAY), Manulife (MFC), and The Travelers (TRV) in a single session. With the shares caught in a notable downdraft, attention now turns to whether MET can find its footing after this outsized drop, or whether further weakness keeps it lagging relative to its broader peer set.
Why MetLife, Inc. Price is Moving Lower
MetLife, Inc. is facing renewed selling pressure following a recent institutional move: Freemont Management S.A. trimmed its holdings on Feb. 13, 2026. Even a single disclosed reduction can weigh on sentiment in a large, widely held insurer, particularly when it reinforces a risk-off posture toward Financials. With trading activity running below normal — roughly 1.15 million shares versus a 90-day average near 3.58 million — down moves can feel more decisive, as fewer incremental buyers are available to absorb supply.
On the fundamental side, a headline revenue growth rate of 27.57% has not been enough to dispel concerns about profitability. MetLife's profit margin of 4.38% leaves little cushion if claims trends, investment spreads, or operating costs shift in the wrong direction — a vulnerability that tends to matter more when investors are scrutinizing insurers for earnings quality rather than top-line expansion. In that environment, strong growth can read as lower quality if it fails to translate into healthier margins and more durable returns.
Sector dynamics add further headwinds. Large insurance competitors can attract incremental flows whenever investors rotate within the group, and that ongoing competition for capital can pressure relative laggards. For MetLife, the combination of an institutional trim, thin volume, and margin vulnerability keeps caution elevated and tilts near-term price action to the downside.
What is the MetLife, Inc. Rating - Should I Sell?
Weiss Ratings assigns MET a B rating. Current recommendation is Buy. Caution is still warranted though; MET's overall B rating rests on a mixed foundation, with shareholder outcomes trailing the company's headline business figures. The most notable concern is the Weak Total Return Index, which signals that past performance has not consistently rewarded investors for the risk they have assumed. Put simply, even during periods of operational stability, the stock's risk-adjusted payoff has been less than convincing.
Operationally, MetLife presents a divided profile. The Fair Growth Index reflects a reality where expansion has not translated cleanly into profitability: revenue growth of 27.57% stands in sharp contrast to a thin 4.38% profit margin. The Good Efficiency Index and a 12.02% ROE are respectable figures, but they do not resolve the challenge of converting scale into meaningfully stronger bottom-line results. At 16.80x forward P/E, the valuation is not stretched, yet it leaves limited room for disappointment should margins or underwriting results come under pressure.
Risk controls represent a relative bright spot, anchored by the Excellent Solvency Index, while the Fair Volatility Index suggests the ride can still turn bumpy during periods of market uncertainty. Within Financials sector, MET is on equal footing with Ping An Insurance (Group) Company of China, Ltd. (PNGAY, B) and Manulife Financial Corporation (MFC, B), though it falls short of The Travelers Companies, Inc. (TRV, A-). The takeaway for investors is straightforward: MET's balance sheet strength is a genuine asset, but it has not been sufficient on its own to produce stronger risk-adjusted returns.
About MetLife, Inc.
MetLife, Inc. (MET) is a large, diversified insurance provider in the Financials sector, with operations spanning life insurance, employee benefits, and related protection products. Its core offerings include term and permanent life coverage, group life and disability, dental and vision plans, accident and critical illness coverage, and a broad range of workplace benefits distributed through employers and benefits platforms. MetLife also provides annuity products and other solutions designed to address income and longevity needs, as well as select investment-related products offered through its insurance operations.
The company maintains an extensive distribution footprint encompassing employee-benefits channels, brokers and consultants, direct-to-consumer marketing, and institutional relationships. It operates through a mix of U.S. and international businesses, including a meaningful presence across Asia, Latin America, and Europe, Middle East and Africa, serving both individual and corporate clients. MetLife's scale and brand recognition support access to large employer groups, though the business remains subject to competitive pricing pressures, claims experience, and underwriting discipline across multiple lines of coverage.
Beyond traditional insurance, MetLife offers retirement and savings solutions and provides services that support plan administration and benefits management for employers. Like many large insurers, it relies on disciplined risk selection, precise policy pricing, and efficient servicing to sustain product competitiveness — all while navigating regulatory oversight and complex product structures that can make performance less predictable across economic cycles.
Investor Outlook
Even with a Weiss Rating of B (Buy) for MetLife, Inc. (MET), this is a setup that warrants caution: watch how the stock behaves around recent support and resistance levels, and whether Financials sentiment turns on rate expectations or credit conditions. Also monitor whether the factors behind the B-grade stay intact if volatility rises or underwriting and investment results soften. See full rankings of all B-rated Financials stocks inside the Weiss Stock Screener.
--